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Introduction
The patients with extensive burn injuries always have 
limited donor sites for skin grafting. Delayed wound closure, 
due to the lack of  autologous skin grafts and the inability of  
skin cell migration from neighboring healthy tissue, could 
result in severe wound contraction and scarring.[1-3]
Skin tissue engineering aims to develop an alternative for 
A B S T R A C T
Current dermal regenerative scaffolds provide wound coverage, and structural support and guidance for tissue repair, but usually 
lack enough bio-signals needed for speeding up skin cell growth, migration, wound closure, and skin regeneration. In this study, 
an androgen receptor (AR) inhibitor called ASC-J9 is used to demonstrate the concept and feasibility of fabricating drug-loaded 
scaffolds via electrospinning. Inhibition of androgen is known to promote skin wound healing. The novel ASC-J9 - loaded porous 
scaffold was fabricated for skin wound repair using electrospun fibers of collagen and polycaprolactone (PCL) blend. Our preliminary 
results indicated that ASC-J9 - loaded scaffolds facilitated more efficient attachment and ingrowth of dermal fibroblasts, compared 
to the control collagen-PCL scaffold. A significant increase of cell proliferation was observed with the drug-loaded scaffold over a 28-
day period. The drug-loaded scaffold also accelerated keratinocyte migration and wound closure in a contraction-inhibited mouse 
wound model over 21 days. The data indicated a sustained release of ASC-J9 from the scaffold and its potential to accelerate wound 
healing by promoting cell proliferation and migration over an extended period of time. More importantly, our results proved the 
concept and feasibility of fabricating drug-releasing or bioactive dermal scaffolds for more effective wound healing.   
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skin grafts that can mimic natural skin structure, facilitate 
wound healing and tissue regeneration, and restore skin 
function. Dermal regenerative bioscaffold, stem cell 
resources, and various biofactors are essential for skin 
tissue engineering. Currently, there are many researches 
of  skin engineering that have focused mainly on scaffold 
structures and morphology, especially the properties such as 
porosity and pore size, and how they influence cell-scaffold 
interactions. While current dermal regenerative templates 
promote wound healing and provide wound closure, they 
are still far from being perfect. The niche environment of  
current dermal scaffolds usually lacks a sufficient level 
of  biological cues that could induce or stimulate cell 
migration, proliferation, and differentiation to accelerate 
wound healing and better skin regeneration. Consequently, 
delayed wound healing could lead to severe scarring and 
wound contraction. The unsatisfactory outcome, in fact, 
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highlighted an aspect of  skin tissue engineering that needs 
further improvement, which is to develop a better scaffold 
that could provide biological cues as well as a temporal and 
spatial environment for scaffolding of  cells.
Deliveries of  various biofactors including epidermal growth 
factor (EGF) and fibroblast growth factor (FGF) have been a 
trendy strategy for promoting angiogenesis, wound healing, 
and tissue engineering. Hormones and growth factors 
including androgen, EGF, FGF, and angiogenic factors are 
known to play critical roles in skin regeneration. They could 
stimulate the proliferation and migration of  keratinocytes, 
fibroblasts, and endothelial cells to promote angiogenesis 
and wound healing.[4,5] The regulation of  androgen and its 
receptors could modulate wound healing.[6] The hydrogel 
or gelatin microsphere was proved effective as matrices for 
controlled delivery of  growth factors for wound healing.[7,8] 
However, to produce a growth factor-releasing electrospun 
scaffold remains a challenge as the growth factor could 
lose its bioactivity during the harsh process of  scaffold 
fabrication.[7] In this study, we tried an alternative strategy 
to incorporate a chemical compound that was demonstrated 
to regulate the activities of  androgen in wound healing. The 
drug chosen for this study was ASC-J9 (5-hydroxy-1,7-bis 
(3,4-dimethoxyphenyl)-1,4,6-heptatrien-3-one), a synthetic 
anti-androgen agent[8] which enhances androgen receptor 
(AR) degradation.[6,9] It is of  the same family as flutamide 
that blocks the interaction between androgens and their 
receptors to promote wound closure.[6] ARs have been found 
to be expressed in the keratinocytes and dermal fibroblasts 
of  healing skin[6] and are able to induce collagen expression 
in dermal fibroblasts.[10] ARs are also thought to indirectly 
modulate fibroblast proliferation in addition to collagen 
synthesis via Transforming growth factor (TGF)-1.[11-13] 
A previous study showed that topical application of  an 
ASC - J9 - containing cream accelerated re-epithelialization 
which was likely to be a result of  suppression of  local tumor 
necrosis factor (TNF)- expression.[9] Due to ASC-J9’s 
chemical stability and advantageous results in promoting 
wound healing, it was chosen for this study to demonstrate 
the principle of  drug release from electrospun scaffolds for 
wound healing.
The aim of  this study was, therefore, to develop a bioactive 
scaffold which harnessed the properties of  ASC-J9 to 
accelerate wound healing in a collagen - polycaprolactone 
(PCL) - ASC-J9 (CPA) composite scaffold. The bioactive 
scaffolds could potentially facilitate more efficient cell 




Rat tail collagen type I was purchased from BD Biosciences, 
San Jose, USA. PCL (Mn 80,000), 1,1,1,3,3,3-hexafluoro-
2-propanol (HFP), diphosphate buffer solution (DPBS), 
phosphate buffer solution (PBS), Dulbecco’s modified 
eagle’s medium (DMEM), sodium cacodylate buffer 
trihydrate, penicillin/streptomycin/neomycin, and 
hexamethyldisilazane (HMDS) were obtained from Sigma-
Aldrich, Castle Hill, Australia. Paraformaldehyde and 
glutaraldehyde were purchased from ProSciTech, Kirwan, 
Australia. Triton solution, ProLong® Gold antifade reagent 
with 4,6-diamidino-2-phenylindole (DAPI), and fetal 
bovine serum (FBS) were obtained from Life Technology, 
Mulgrave, Australia. ASC-J9 was purchased from Sapphire 
Biosciences, Waterloo, Australia. Primary human dermal 
fibroblasts (HDFs) were isolated and cultured in this study 
following the approval of  Concord Hospital Human Ethics 
Committee.
Production and characterization of collagen-PCL (CP) and 
collagen-PCL-(ASC-J9) (CPA) scaffolds
Collagen was chosen for its well-known, cell-interactive 
properties and PCL for its mechanical strength and 
biodegradable,  biocompatible,  and  bioabsorbable 
characteristics. 
Polymer solutions were prepared by dissolving polymers 
in HFP: 7.5% (w/v) collagen and 7.5% (w/v) PCL for 
CP scaffolds and addition of  0.1 mg/ml ASC-J9 to the 
CP solution to form the drug-loaded CPA scaffolds.[9] 
The solution was loaded into a 1-ml syringe with a blunt 
18-gauge needle attached. Flow rate was regulated at 
3 ml/h and dispensed volume at 0.51 ml using a single-
syringe infusion pump (SP100iZ; World Precision 
Instruments Inc., FL, USA). The needle was connected 
to a 20 kV positive power supply (Gamma High Voltage 
Research, Inc., Ormond Beach, FL, USA) and directed 
at a negatively charged, 30-mm-diameter, circular, brass 
collector at a distance of  25 cm. The d rug-loaded, porous, 
composite scaffold was examined in vitro with human 
dermal fibroblasts and in vivo in a mouse model.
Analysis of scaffold surface morphology by scanning 
electron microscopy
The surface morphologies of  electrospun CP and CPA 
scaffolds were examined using a JEOL scanning electron 
microscope (SEM). Specimens were mounted on 
aluminum sample stubs and sputter-coated with platinum 
Burns & Trauma • September 2013 • Vol 1 • Issue 2 97
Chong, et al.: Drug-loaded electrospun bioscaffold for wound healing 
using a JFC-1600 Auto Fine Coater (JEOL DATUM, 
Tokyo, Japan) prior to examination under the SEM at a 
voltage of  15 kV.
Samples with attached HDFs were transferred to 10-ml 
centrifuge tubes and residual culture medium was replaced 
by sterile PBS (pH 7.4). After rinsing three times with PBS, 
the HDFs attached to the surface of  the materials underwent 
an initial fixation by addition of  2.5% (w/v) glutaraldehyde 
in 0.1 M sodium cacodylate buffer trihydrate for 30 min (first 
fix). Samples were then rinsed with PBS before a second 
fixation using 2% (w/v) osmium tetroxide in 0.2 M sodium 
cacodylate buffer for 1 h. Cells attached to the samples 
were washed with sodium cacodylate buffer trihydrate and 
dehydrated using a series of  ethanol dilutions (50–100%) 
for 5 min, twice per dilution. Specimens were finally dried 
in HMDS and prepared and mounted as described above.
Quantification of pore size and fiber diameter of the 
scaffolds
Pore size and fiber diameter of  CP and CPA scaffolds were 
quantified under SEM using an established method.[14] The 
widths of  30 fibers and the diameters of  30 pores randomly 
chosen from SEM images were measured.
Cell culture
HDFs were obtained from donated skin biopsies of  patients 
at the Burns Unit in Concord Repatriation General Hospital 
with approval from the Hospital Human Ethics Committee.
CP and CPA scaffold cells were seeded at 1 × 104 cells/cm2 in 
triplicate. Seeded scaffolds were incubated at 37°C, 5% CO
2 
in DMEM supplemented with 10% (v/v) FBS and 100 U 
penicillin/0.1 mg streptomycin/0.2 mg neomycin/ml, with 
the culture medium replaced every 2 days. The cells in the 
scaffolds were harvested by trypsin digestion and the cell 
numbers determined by trypan blue staining and viable 
counting on days 1, 5, 7, 14, and 28 post-seeding.
Analysis of HDF ingrowth on scaffolds 
HDF ingrowths in the CP and CPA scaffolds were analyzed 
using DAPI staining and fluorescence microscopy. 
HDF-seeded scaffolds were collected and washed 
twice with DPBS, followed by a 15-min fixation in 4% 
(v/v) paraformaldehyde. After fixation, samples were 
permeabilized in 0.2% (v/v) Triton solution for 15 min. The 
cell-fixed scaffold was then washed in DPBS three times 
and air-dried overnight. The nuclei of  HDF-seeded scaffolds 
were stained using ProLong Gold antifade reagent with 
DAPI and air-dried overnight in the dark. The DAPI-stained 
HDFs on scaffolds were visualized and photographed using 
a fluorescence microscope (Axiovert 200; Carl Zeiss, Inc., 
Jena, Germany)
Animal model
A mouse model of  wound healing was used to evaluate 
biocompatibility, efficacy, and cellularization of  CP and 
CPA scaffolds. Specific pathogen-free, female and male 
BALB/c mice, aged 8 weeks and weighing 21.0 ± 1.9 g 
(female)/25.0 ± 2.7 g (male) were purchased from the 
Australian Animal Resources Centre. All animals were 
acquired, housed, and studied under a protocol approved 
by the SSWAHS Animal Welfare Committee in Sydney, 
Australia. Each mouse was individually anesthetized by 
intraperitoneal injection of  a mixture of  ketamine (75 mg/
ml) and xylazine (10 mg/ml) at 0.01 ml/g of  body weight. 
The dorsal hair was shaved and the skin cleaned with 
Betadine solution and then washed with sterile saline. Two 
1 × 1 cm2 full-thickness wounds were surgically created on 
the dorsal area with a frame of  silicone splint stitched to 
each wound [Figure 1]. The frame was purposely applied 
to inhibit the mouse wound healing by contraction and 
enable the wound closure mainly by cell migration from 
the surrounding skin.
One wound was grafted with the CP scaffold and the other 
with the CPA scaffold. Each wound was then covered with 
IV3000 wound dressings (Smith and Nephew, North Ryde, 
Australia) for 5 days. After surgery, each mouse was caged 
individually for the first 2 days and then two mice per cage 
thereafter with free access to food and water. Carprofen (5 
mg/kg) was given at the time of  anesthetization and then 
on the following day post-surgery for analgesia. Wound 
area was measured using Visitrak Grid (Smith and Nephew) 
on days 0, 3, 5, 7, 14, and 21 post-surgery. Wound area at 
each time point was then normalized to the original wound 
area, defined as the wound area at time points divided by 
the initial wound area ×100. The mice were sacrificed and 
skin biopsies collected for histological analysis on days 7, 
14, and 21 after surgical grafting.
Histology
Skin biopsies were fixed in 10% formalin for 24 h and 
the samples from in vitro experiments were fixed in 4% 
paraformaldehyde with DPBS washes before and after 
fixation. All samples were then dehydrated with ethanol 
solutions of  increasing gradient concentrations and then 
in xylene. The dehydrated samples were embedded in 
paraffin wax and sectioned. Sections of  4 μm in thickness 
were then deparaffinized and stained using Hematoxylin 
and Eosin.
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Statistical analysis
Data are expressed as mean ± standard deviation. 
Statistically significant differences were determined by t-test 
and one-way analysis of  variance (ANOVA). Statistical 
significance was accepted at P < 0.05 and indicated in the 
figures as *(P < 0.05) and **(P < 0.01).
Results
Characterization of CP and CPA scaffolds [Figure 2]
During the electrospinning processes, the CPA blend was 
injected to the negatively charged brass collector to fabricate 
porous scaffold. The polymer fibers set very quickly. After 
peeling the scaffold off  the collector, no residual drug 
power or CPA polymer was observed in the electrospinning 
system, indicating the incorporation of  ASC-J9 in the 
composite fibers. 
CP scaffolds had a pore diameter range of  1.0-13.6 μm and 
a fiber diameter range of  0.5-1.8 μm, and CPA scaffolds 
had a pore diameter range of  0.9-4.7 μm and a remarkable 
decrease in fiber diameter to the range of  0.1-0.3 μm. 
The CP fibers were mainly circular and thread-like with 
occasional flat, ribbon-like fibers, and were uniform except 
for occasionally thinner fibers, whereas CPA fibers were 
only circular with a much larger range in fiber size.
It was also observed on SEM examination that CP and CPA 
fibers had a difference in surface morphology. CP fibers had 
a uniformly smooth surface, while CPA fibers demonstrated 
relatively rough and irregular surface.
Interaction of human dermal fibroblasts with electrospun 
scaffolds
SEM analysis and DAPI staining showed the attachment 
and proliferation of  HDFs in both scaffolds [Figure 3]. 
Subconfluent HDF growth on CP scaffolds was seen by 
day 14 and HDF ingrowth in CP scaffolds was limited 
throughout the time course. However, increased attachment 
and proliferation was seen on CPA scaffolds at days 7 
and 14, and significantly more HDFs infiltrated the CPA 
scaffolds in comparison to CP scaffolds.
Cell numbers increased over time on both CP and CPA 
scaffolds [Figure 4]. Cell numbers on CP scaffolds increased 
twofold at days 7 and 14 post-seeding and about 2.5-fold 
by 4 weeks post-seeding. Cell numbers on CPA scaffolds 
increased 2.8-fold between days 1 and 14 post-seeding and 
by 6-fold over 4 weeks.
Figure 1: Diagrammatic representation of dorsal open wounds (pink) 
splinted with silicone frames (outline in blue) and attached to skin with 
silk sutures (black) at the corners.
Figure 2: SEM analysis of electrospun collagen (7.5% w/v) and PCL 
scaffold (7.5% w/v) without (a, b) and with (c, d) ASC-J9 (0.1 mg/ml) 
incorporated (a and c, ×5000; b and D, ×15,000).
a b
dc
Figure 3: Human dermal fi broblasts in CP and CPA scaffolds by SEM 
and DAPI staining. Sample images represent, respectively, the HDFs 
on CP scaffold at day 7 (a, e, i) and day14 (b, f, j), and HDFs on CPA 
scaffold at day 7 (c, g, k) and day 14 (d, h, l).
a b c d
e f g h
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Animal model study of CP and CPA scaffolds
In animal models, electrospun CPA grafts accelerated wound 
healing, compared to open wounds and wounds grafted 
with electrospun CP scaffolds [Figure 5]. Raw wound area 
in CPA-grafted animals was significantly reduced by days 
7, 14, and 21, compared to CP-grafted wounds. By day 21, 
the wounds in CPA-grafted mice were almost fully healed 
while over 30% of wound areas in both CP-grafted and open 
wound control groups were still not open.
In the animal model, the silicone splint inhibited wound 
healing by contraction. Comparing CPA-grafted mice to 
CP-grafted mice, CPA scaffolds accelerated keratinocyte 
migration over the wound edge toward the central area 
for more effective wound closure and re-epithelialization 
[Figure 6]. 
Discussion
In addition to scaffolds and skin progenitor cells, biofactors, 
including growth factors, hormones, and inflammatory 
regulators, and their regulation are critical for wound 
healing and skin regeneration. While bioscaffolds provide 
structural support, and guidance for the attachment and 
migration of  dermal fibroblasts and keratinocytes, the 
biochemical factors and their regulation further induce and 
promote the cell proliferation, ingrowth, and differentiation 
for more effective wound healing and regeneration of  
dermal and epidermal tissues. In cell culture, the defined 
media provide a rich source of  essential nutritious 
ingredients, biofactors, and other supplements. Under in vivo 
situation, the essential supply needed for wound healing 
and skin regeneration could only depend on the diffusion 
of  nutritious ingredients, vascularization, and blood supply 
in the wound region. Fabrication of  bioactive factors in the 
scaffold would provide the cells with extra supplements 
to ensure more effective cell migration, proliferation, or 
differentiation in addition to bioscaffolding and, therefore, 
accelerate tissue regeneration and wound closure.
Electrospun CP and CPA scaffolds were produced and 
they displayed fibrous, porous structures with fiber 
diameter ranging from 0.1 to 4.0 μm [Figure 2]. The 
electrospun fibers were morphologically similar to native 
extracellular matrix fibers and provided a large surface area 
to volume ratio, thereby promoting cell interactions and 
new tissue formation.[15,16] HDFs were shown to attach, 
migrate, and proliferate on the CP scaffold [Figure 3a, b] 
with enhanced cell proliferation, compared to PCL only 
scaffolds (data not shown). This finding suggested that 
the collagen polymer protruding on the surface of  CP 
Figure 4: HDF proliferation on CP and CPA scaffolds over 28 days 
(n = 2). The cell proliferation in CPA at day 14, 21, and 28 were 
signifi cantly higher.
Figure 5: Wound area profi le over 21 days of CP- and CPA-grafted 
wounds. CPA accelerated wound closure in mice (n = 3-4, *P < 0.05 
and **P < 0.01).
scaffolds enhanced surface hydrophobicity and resulted 
in favorable cell interaction, proliferation, and migration. 
SEM analysis of  seeded fibroblasts at day 14 on CP 
scaffold revealed large numbers of  attached cells in contact 
with the surface [Figure 3b]. Pronounced flattening and 
Figure 6: Histological analysis of wound healing following CP and CPA 
grafting. Accelerated keratinocyte migration and re-epithelialization was 
seen in CPA-grafted mice. (a) CPA at day 5, (b) CPA at day 7, (c) CPA 
at day 14, and (d) CP at day 14. Each large arrow points to wound 
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spreading of  cells was observed at days 7 and 14 [Figure 
3a, b], obscuring the underlying polymer surface, with 
cellular processes connecting the flattened cell bodies. This 
behavior suggests strong cell adhesion with the underlying 
substrate via local contacts and provides a measure of  
the biocompatibility of  the polymer. However, HDF 
penetration of  the CP scaffolds was not observed due to 
either the small pore size in the range of  1.0-13.6 μm of  
the scaffolds, uneven distribution of  collagen throughout 
the fibers, or the limited time available for cell ingrowth 
to occur. These findings are broadly in line with those 
of  Powell et al.[17] who found that collagen-PCL solution 
with more than 30% (w/v) PCL resulted in separation 
of  the collagen and PCL phases within the fibers. The 
lack of  uniformity may slow or impair cell attachment 
and migration, as the cells have to attach to a natural 
polymer domain and then a synthetic polymer domain. 
Furthermore, the harsh processes of  CP electrospun 
fabrication could also reduce the effectiveness of  collagen 
element in the CP composite for cell migration.
In the study, we explored the feasibility of  making a 
bioactive scaffold, not only for drug delivery but also to 
improve the scaffold’s functionality for better cell growth, 
migration, and accelerated wound healing. An important 
aspect of  drug delivery is the stability and activity of  the 
drug during formation and throughout the release period. 
Although electrospun scaffolds were used for controlled 
delivery of  low-molecular-weight hydrophilic drugs, 
growth factors, and proteins, to retain a lasting activity 
of  delivered factors has always been a challenge due to 
the harsh processes of  fabrication.[17] Compared to other 
protein factors such as EGF and FGF, the AR inhibitor, 
ASC-J9, is a chemically stable compound that could better 
survive the process and retain its activity. Under SEM, 
the CPA scaffolds displayed uniformly thinner fibers and 
relatively more porous structures, compared to CP scaffolds 
[Figure 2]. In comparison with CP fibers, fiber morphology 
by SEM analysis revealed that CPA fibers were thinner with 
much rougher fiber surface. The absence of  obvious drug 
particles on the CPA fiber surface suggested that dispersed 
ASC-J9 was effectively coated by collagen-PCL polymers 
during fiber formation. The in vitro data demonstrated 
that CPA scaffolds enhanced faster cell proliferation and 
better cell–matrix interaction over the time course of  28 
days, with significantly increased overall cell numbers in 
the scaffolds post-cell seeding, particularly from day 7 
onward. This demonstrated that the drug and scaffold were 
not cytotoxic to the cells. These findings reflected a highly 
efficient delivery and sustained release of  active ASC-J9 
from CPA scaffolds over 4 weeks, which was also evident 
by DAPI staining that revealed HDFs migrated through 
to the central region of  the CPA scaffolds on day 7 and 
by day 14 post-cell seeding. The observation of  gradually 
accelerated cell migration and distribution in CPA scaffolds 
was encouraging, as it proved the feasibility of  utilizing 
CP electrospun scaffolds for incorporation and delivery of  
bioactive molecules to promote cellular activities including 
cell–scaffold interaction, cell proliferation, and migration.
In our animal model, CPA scaffolds were superior to 
CP scaffolds in promoting wound healing. Significantly 
accelerated migration of  epidermal migration and wound 
closure was associated with CPA-grafted wounds, with 
only a mild inflammatory response observed, when 
compared to CP scaffolds. The newly formed skin had 
a well-differentiated epidermis with multiple layers of  
keratinocytes and a vascularized neodermis, both important 
components for functional skin. Our in vivo findings 
together with the above in vitro data were in agreement 
with the previous studies which demonstrated that topical 
application of ASC-J9 cream on mice resulted in accelerated 
wound repair via increased fibroblast proliferation and 
keratinocyte migration following inhibition of AR function.[9] 
In comparison to topical treatment using cream or gel, CP 
electrospun scaffolds could serve as a good delivery device for 
not only structural scaffolding but also sustained delivery of  
bioactive compounds or molecules with minimal burst release 
for more effective wound healing and re-epithelialization.
Taken together, accelerated fibroblast proliferation, re-
epithelialization, and wound healing were associated with 
grafting CPA scaffolds. These results were achieved via the 
sustained release of  ASC-J9 from CPA scaffolds into the 
wound area to promote cell proliferation and migration 
in addition to the structural support and guidance. More 
importantly, this study demonstrated the principle of  
using electrospun CP scaffolds for releasing drugs or 
active molecules into the wound. It could enable the tissue 
regenerative scaffold, with extra biofactors or cues, to 
speed up skin cell growth, migration, wound closure, and 
re-epithelialization. Future studies will focus on refining 
the process to improve the fabrication of  CP scaffolds for 
delivering ASC-J9, and possibly multiple biofactors, as 
well as characterizing host - scaffold interactions including 
inflammation, cell recruitment, and synthesis of  key 
proteins in relation to wound healing, skin regeneration, 
and scar development. 
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